相似文献
1
Antivascular therapy for epithelial ovarian cancer.
J Oncol. 2010;2010:372547. doi: 10.1155/2010/372547. Epub 2009 Dec 23.
2
Antiangiogenic therapies in epithelial ovarian cancer.
Cancer Control. 2011 Jan;18(1):31-43. doi: 10.1177/107327481101800105.
3
Antiangiogenic agents should be integrated into the standard treatment for patients with ovarian cancer.
Ann Oncol. 2011 Dec;22 Suppl 8:viii65-viii68. doi: 10.1093/annonc/mdr529.
4
Novel antiangiogenic therapies in ovarian cancer.
Womens Health (Lond). 2012 Jul;8(4):447-53. doi: 10.2217/whe.12.26.
5
The potential role of antivascular therapy in the adjuvant and neoadjuvant treatment of cancer.
Semin Oncol. 2001 Feb;28(1):93-105. doi: 10.1016/s0093-7754(01)90047-8.
6
[Antivascular strategies--a new concept for diagnosis and therapy of head and neck cancer. A review].
Laryngorhinootologie. 2002 Jul;81(7):509-15. doi: 10.1055/s-2002-33284.
7
The search for biomarkers to direct antiangiogenic treatment in epithelial ovarian cancer.
Gynecol Oncol. 2014 Nov;135(2):349-58. doi: 10.1016/j.ygyno.2014.08.033. Epub 2014 Aug 30.
8
Antiangiogenic therapies in ovarian cancer.
Memo. 2016;9(3):139-143. doi: 10.1007/s12254-016-0282-4. Epub 2016 Sep 15.
9
Antiangiogenic agents and vascular disrupting agents for the treatment of lung cancer: a review.
J Thorac Oncol. 2010 Jan;5(1):129-39. doi: 10.1097/JTO.0b013e3181c59a60.
10
Novel targeted therapies in epithelial ovarian cancer: from basic research to the clinic.
Expert Rev Endocrinol Metab. 2007 Mar;2(2):225-238. doi: 10.1586/17446651.2.2.225.
引用本文的文献
1
Investigating impact of Vascular Endothelial Growth Factor Polymorphisms in Epithelial Ovarian Cancers: A Study in the Indian Population.
PLoS One. 2015 Jul 9;10(7):e0131190. doi: 10.1371/journal.pone.0131190. eCollection 2015.
2
Optimizing molecular-targeted therapies in ovarian cancer: the renewed surge of interest in ovarian cancer biomarkers and cell signaling pathways.
J Oncol. 2012;2012:737981. doi: 10.1155/2012/737981. Epub 2012 Feb 6.
3
Utility of vascular endothelial growth factor inhibitors in the treatment of ovarian cancer: from concept to application.
J Oncol. 2012;2012:540791. doi: 10.1155/2012/540791. Epub 2011 Sep 26.
4
Role of endoglin and VEGF family expression in colorectal cancer prognosis and anti-angiogenic therapies.
World J Clin Oncol. 2011 Jun 10;2(6):272-80. doi: 10.5306/wjco.v2.i6.272.
5
Targeting solid tumors with non-pathogenic obligate anaerobic bacteria.
Cancer Sci. 2010 Sep;101(9):1925-32. doi: 10.1111/j.1349-7006.2010.01628.x.
本文引用的文献
1
A phase II study of ramucirumab (IMC-1121B) in the treatment of persistent or recurrent epithelial ovarian, fallopian tube or primary peritoneal carcinoma.
Gynecol Oncol. 2014 Sep;134(3):478-85. doi: 10.1016/j.ygyno.2014.06.029. Epub 2014 Jul 10.
2
Safety and efficacy of first-line bevacizumab with FOLFOX, XELOX, FOLFIRI and fluoropyrimidines in metastatic colorectal cancer: the BEAT study.
Ann Oncol. 2009 Nov;20(11):1842-7. doi: 10.1093/annonc/mdp233. Epub 2009 Apr 30.
3
In vitro metabolism of the novel, highly selective oral angiogenesis inhibitor motesanib diphosphate in preclinical species and in humans.
Drug Metab Dispos. 2009 Jul;37(7):1378-94. doi: 10.1124/dmd.108.025742. Epub 2009 Apr 16.
4
Hypothyroidism related to tyrosine kinase inhibitors: an emerging toxic effect of targeted therapy.
Nat Rev Clin Oncol. 2009 Apr;6(4):219-28. doi: 10.1038/nrclinonc.2009.4.
5
The VEGF pathway and the AKT/mTOR/p70S6K1 signalling pathway in human epithelial ovarian cancer.
Br J Cancer. 2009 Mar 24;100(6):971-8. doi: 10.1038/sj.bjc.6604921. Epub 2009 Feb 24.
6
Beyond chemotherapy: targeted therapies in ovarian cancer.
Nat Rev Cancer. 2009 Mar;9(3):167-81. doi: 10.1038/nrc2583.
7
Preclinical studies and clinical utilization of monoclonal antibodies in epithelial ovarian cancer.
Gynecol Oncol. 2009 Jun;113(3):384-90. doi: 10.1016/j.ygyno.2009.01.008. Epub 2009 Feb 20.
8
Angiogenesis-related gene expression profile with independent prognostic value in advanced ovarian carcinoma.
PLoS One. 2008;3(12):e4051. doi: 10.1371/journal.pone.0004051. Epub 2008 Dec 29.
9
New response evaluation criteria in solid tumours: revised RECIST guideline (version 1.1).
Eur J Cancer. 2009 Jan;45(2):228-47. doi: 10.1016/j.ejca.2008.10.026.
10
Preclinical anticancer activity of the specific endothelin A receptor antagonist ZD4054.
Anticancer Drugs. 2009 Feb;20(2):83-8. doi: 10.1097/CAD.0b013e328320791c.
Zotero 插件
